Uterine Cancer Drugs Market Size, Share, Demands and Gross Margin 2026



Uterine cancer is one of the most common gynecologic malignancy among female cancer patients. This uterine cancer is of two types: endometrial cancer and uterine sarcoma. Endometrial cancer is caused due to uncontrolled growth of inner linings of uterus. Endometrial cancer is often curable, however, uterine sarcoma is rare cancer, which develops in the muscle and supporting tissues of the uterus (womb). According to National Cancer Institute, Megestrol Acetate is only drug approved by U.S. Food and Drug Administration (FDA) for the treatment of endometrial cancer till March 2016. Diagnosis of both types of uterine cancer is done through endometrial biopsy, colposcopy or Pap smear screening test.

Uterine Cancer Drugs Market Drivers

Increasing funding for cancer research, rising insurance coverage, and increasing number of new targeted cancer drugs are supporting the revenue growth of uterine cancer drugs market size. For instance, National Cancer Institute, in 2015, invested around US$ 4,480 million on cancer research, which include uterine cancer, cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukemia, and ovarian cancer. Furthermore, according to the American Cancer Society, U.S. has spent around US$ 87.8 billion in 2014, on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.

Chemotherapy is the most recommended therapy suggested for treatment of uterine sarcomas. However, chemotherapy may not work in certain types of uterine sarcoma. Chemotherapy for uterine sarcoma is often conducted in the earlier stages of cancer. Various chemotherapy drugs used in the treatment of uterine sarcoma include Paclitaxel (Taxol), Docetaxel (Taxotere), Dacarbazine (DTIC), Liposomal doxorubicin (Doxil), Epirubicin (Ellence), and among others.

Uterine Cancer Drugs Market - Regional Analysis

Geographically, uterine cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. According to World Health Organization (WHO) 2018 data findings, cervical cancer is the fourth most frequent type of cancer in women, which accounted for an estimated 530,000 new cases in 2012, representing 7.9% of all female cancers. Furthermore, according to WHO: 2018, around 90% the 270,000 deaths from cervical cancer in 2015 are occurred in low- and middle-income countries. Furthermore, the prevalence of endometrial cancer is higher in developed economics such as the in North America and the Europe, owing to changing lifestyles of women in these countries. The prevalence of uterine cancer is more common in women aged 50 years and above.

Thus, uterine cancer drugs market is expected to exhibit significant growth in North America and Europe region, followed by Asia Pacific region. North America holds dominant position in uterine cancer drugs market, owing to the increasing incidence rate of endometrial cancer cases in these region. For instance, according to the International Agency for Research on Cancer: 2014 data findings, published by World Cancer Research Fund International, in January 2015, around 53% of the endometrial cancer cases were reported in developed economies, which includes U.S., Luxemburg, Norway, Poland, and among others. Moreover, according to the same source incidence of endometrial cancer was fond to be highest in Northern America and Europe and the lowest incidence in Africa and Asia. Furthermore, according to the data published in Journal of the National Cancer Institute in April 2018, North America, Eastern, and Northern Europe witnessed highest rate of endometrial cancer incidence and lowest rate were reported in middle-income countries including South Africa and India.

Uterine Cancer Drugs Market Competitive Landscape

Some of the key players operating in the uterine cancer drugs market include Merck & Company, Inc., Actiza Pharmaceutical Private Limited, United Biotech Pvt Ltd, Elder Pharmaceuticals Ltd, Par Pharmaceutical Companies, Inc. and among others.




Uterine Cancer Drugs Market Taxonomy:

By Indication:

Endometrial Cancer
Uterine Sarcoma

By Product Type:

Megestrol Acetate
Dacarbazine (DTIC)
Docetaxel (Taxotere)
Gemcitabine (Gemzar)
Epirubicin (Ellence)
Paclitaxel (Taxol)
Temozolomide (Temodar)
Others

By Distribution Channel:

Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

By Geography:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Comments

Post a Comment

Popular posts from this blog

Cosmetic Dentistry Market Enhancement in Various Sector 2018 to 2026

Image
Cosmetic dentistry refers to any dental work that improves the appearance of gums or teeth. It focuses on improving dental aesthetics in size, shape, color, position, and alignment. It involves the addition of dental materials such as porcelain veneers, gum grafts, crowns, and bonding to gums or teeth, removal of teeth structure and gums through procedures such as enameloplasty, gingivectomy, teeth whitening, gum depigmentation, laser whitening, and teeth straightening. Laser whitening is more effective as compared to other procedures for teeth whitening. Bonding in cosmetic dentistry involves the adhesion of a dentistry material onto both surfaces of the tooth, which is then sculpted, hardened, and polished. Dental bridges are used to replace one or more missing teeth. Bridge, which is made up of abutments can consist of over 3 teeth in total and the average life of bridges is 10 years. Veneers are custom made ultra-thin porcelain laminates that are bonded directly to the t...
Read more

Telemedicine Market to Witness Robust Expansion Throughout the Forecast Period 2018-2026

Image
Telemedicine involves the use of information technology and telecommunication for the delivery of healthcare services such as health assessments or consultations over the telecommunications infrastructure. It helps the healthcare professional to diagnose, evaluate and treat patients without the need for an in-person visit and are also very useful to save lives at time of critical care and emergency situations. Telemedicine is of great help for distant rural areas as they help in overcoming the distance barriers to avail medical services at the time of requirement. Telemedicine enables the doctors to be connected through a variety of electronic means, including video conferencing, email and electronic messaging platforms. This reduces the overall cost of medical care for patients and increase healthcare accessibility. Download PDF Brochure Of This Report: https://www.coherentmarketinsights.com/insight/request-pdf/548 Seeing the potential that the telemedicine provid...
Read more